Physician profile
Gaurav M Chandra
NPI 1497166730
$5,389.81
in general payments reported to CMS, 2019-2025
27 companies · $1,738 in 2025
The $1,738 reported for 2025 was more than what a typical Uveitis and Ocular Inflammatory Disease provider received nationally (typical 2025 total: $471).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $266 · 2021: $582 · 2022: $556 · 2023: $984 · 2024: $1,264 · 2025: $1,738.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,986.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,986.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alimera Sciences, INC. | $884.65 | 2020-2024 | Iluvien, Yutiq |
| Regeneron Healthcare Solutions, INC. | $529.64 | 2022-2025 | Eylea Hd, Eylea |
| Sun Pharmaceutical Industries INC. | $437.83 | 2021-2025 | Cequa, Xelpros |
| Bausch & Lomb Americas INC. | $434.65 | 2022-2025 | Xipere, Miebo, Xiidra |
| Ani Pharmaceuticals, INC. | $392.22 | 2025 | Iluvien, Purified Cortrophin Gel, Yutiq |
| Abbvie INC. | $340.60 | 2020-2025 | Ozurdex |
| Alcon Vision LLC | $318.42 | 2021-2025 | Rocklatan, Rhopressa, Eysuvis |
| Harrow Eye, LLC | $278.43 | 2024-2025 | Iheezo, Vevye, Triesence |
| Mallinckrodt Hospital Products INC. | $247.42 | 2021-2025 | Acthar |
| Astellas Pharma US INC | $227.06 | 2023-2025 | Izervay |
| Glaukos Corporation | $221.22 | 2024 | Istent Trabecular Micro-Bypass System Model Is3 |
| Genentech USA, INC. | $219.88 | 2022-2025 | Vabysmo |
| Eyepoint US, INC. | $138.10 | 2021-2022 | |
| Apellis Pharmaceuticals, INC. | $127.79 | 2023-2025 | Syfovre |
| Kala Pharmaceuticals, INC. | $118.47 | 2021 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tarsus Pharmaceuticals, INC. | $65.83 | 2024-2025 | Xdemvy |
| Aerie Pharmaceuticals, INC. | $58.39 | 2021 | |
| Allergan, INC. | $54.34 | 2021 | |
| Amgen INC. | $48.30 | 2025 | Tepezza |
| Novartis Pharmaceuticals Corporation | $45.47 | 2021 | |
| Oyster Point Pharma, INC. | $42.69 | 2022-2024 | Tyrvaya |
| Horizon Therapeutics Plc | $37.89 | 2022-2023 | Tepezza |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $29.99 | 2020 | |
| Biotissue Holdings INC. | $26.18 | 2022 | |
| Eyevance Pharmaceuticals LLC | $23.35 | 2020 | |
| Rxsight INC | $21.09 | 2024 | Rxsight Light Delivery Device (Ldd), Rxsight Injector Handpiece, Rxsight Contact Lens |
| Johnson & Johnson Surgical Vision, INC. | $19.91 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gaurav Chandra listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.